Bluejay Diagnostics (Bluejay Diagnostics) GF Value : $0.00 (As of May. 22, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Bluejay Diagnostics GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-22), Bluejay Diagnostics's share price is $0.5105. Bluejay Diagnostics's GF Value is $0.00. Therefore, Bluejay Diagnostics's Price-to-GF-Value for today is .

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Bluejay Diagnostics is Not Valued.

Bluejay Diagnostics (NAS:BJDX) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Bluejay Diagnostics's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	0.5105	/	0.00
	=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bluejay Diagnostics GF Value Related Terms

Thank you for viewing the detailed overview of Bluejay Diagnostics's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Bluejay Diagnostics (Bluejay Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bluejay Diagnostics Inc (NAS:BJDX) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

360 Massachusetts Avenue, Suite 203, Acton, MA, USA, 01720

Website

https://www.bluejaydx.com

Bluejay Diagnostics Inc is a medical diagnostics company. It is engaged in developing, manufacturing, and marketing of clinical diagnostic products that improve the quality of medical diagnoses. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings. The company is a provider of rapid tests for infectious, inflammatory, and metabolic diseases by the Symphony platform.

Executives

Svetlana Dey	director, 10 percent owner	360 MASSACHUSETTS AVE, SUITE 203, ACTON MA 01720
Indranil Dey	director, 10 percent owner, officer: Chief Technology Officer	360 MASSACHUSETTS AVENUW, SUITE 203, ACTON MA 0170
Frances P Scally	officer: CFO	66 MELANIE LANE, SYOSSET NY 11791
Jason Cook	officer: Chief Technology Officer	360 MASSACHUSETTS AVE, SUITE 203, ACTON MA 01720
Kenneth R Fisher	officer: Chief Financial Officer	67 PROSPECT STREET, PEABODY MA 01960
Douglas Clark Wurth	director, 10 percent owner	4265 SAN FELIPE, SUITE 603, HOUSTON TX 77027
Gordon Winston Kinder	officer: Chief Financial Officer	360 MASSACHUSETTS AVENUE, SUITE 203, ACTON MA 01720
Gary G Gemignani	director	C/O IASO PHARMA INC., 12707 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Fred S Zeidman	director	109 NORTH POST OAK LANE, SUITE 422, HOUSTON TX 77024
Donald R Chase	director	39 TIMBER RIDGE RD., WEST SPRINGFIELD MA 01089